Skip to content
Screener

uniQure QURE Total Liabilities & Equity

Total Liabilities & Equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$300.35M+117%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.87B+8.0%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$230.44M-3.0%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$201.92M+111%
Regenxbio logo
RegenxbioRGNX
$386.62M-33.5%

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Cash & equivalents$413.0M+62.8%
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies
Shareholders' equity
Ordinary shares, €0.05 par value: 100,000,000 shares authorized at June 30, 2026, and 80,000,000 at December 31, 2025, and 69,334,839 and 62,336,717 shares issued and outstanding at June 30, 2026, and December 31, 2025, respectively.4,0863,688
Additional paid-in capital1,841,7451,582,371
Accumulated other comprehensive loss(58,251)(58,222)
Accumulated deficit(1,463,530)(1,328,936)
Total shareholders' equity324,050198,901
Total liabilities and shareholders' equity$985,103$824,908

Item 1.Financial Statements

FAQ

What is uniQure's total liabilities & equity?
uniQure (QURE) reported total liabilities & equity of $985.1M in Q2 2026.
How has uniQure's total liabilities & equity changed year-over-year?
uniQure's total liabilities & equity increased by 68.4% year-over-year, from $584.89M to $985.1M.
What is the long-term trend for uniQure's total liabilities & equity?
Over 5 years (2020 to 2025), uniQure's total liabilities & equity has grown at a 19.4% compound annual growth rate (CAGR), from $340.4M to $824.91M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about uniQure's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude